Replies to post #166041 on Biotech Values

[caravon]

mcbio,

ARQL barely trades above cash now and has other assets beyond tivantinib in wholly-owned AKT and FGFR inhibitors in ongoing Phase 1 trials.

If ARQL management will continue its glorious pipeline development at the same "highly professional" level, we have witnessed so far, AKT and FGFR inhibitors candidates have no a prayer to see a future.

For an example, there are no indications for any ARQL attempt to determine optimum Tiva dosages to treat pts with different cancer diseases. An idea that the highest tolerable xz-inhibitor dosage is an optimum treatment level is an absurd.